Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Cash flows from operating activities:
Net income	$ 1,392.6	$ 1,408.8
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and impairments	119.9	121.1
Acquired in-process research and development	75.0	0.0
Share-based compensation	67.7	45.7
Contingent consideration	4.6	(11.5)
Loss on divestiture of Hillerød, Denmark manufacturing operations	0.0	115.5
Deferred income taxes	36.9	228.0
Unrealized (gain) loss on strategic investments	(62.0)	375.0
Loss on equity method investment	0.0	0.0
Other	45.7	50.7
Changes in operating assets and liabilities, net:
Accounts receivable	(238.4)	(136.6)
Due from anti-CD20 therapeutic programs	(78.6)	0.0
Inventory	62.2	(129.0)
Accrued expenses and other current liabilities	347.4	138.4
Income tax assets and liabilities	223.0	170.3
Other changes in operating assets and liabilities, net	18.5	(171.1)
Net cash flows provided by operating activities	1,467.3	1,459.5
Cash flows from investing activities:
Proceeds from sales and maturities of marketable securities	2,389.3	1,489.2
Purchases of marketable securities	(1,684.7)	(825.0)
Contingent consideration paid related to Fumapharm AG acquisition	0.0	(300.0)
Purchases of property, plant and equipment	(149.7)	(127.1)
Acquired in-process research and development	(75.0)	0.0
Acquisitions of intangible assets	(37.0)	0.0
Proceeds from sales of strategic investments	0.5	0.0
Other	0.5	(1.7)
Net cash flows provided by investing activities	442.9	238.8
Cash flows from financing activities:
Purchases of treasury stock	(2,220.2)	(655.8)
Payments related to issuance of stock for share-based compensation arrangements, net	(29.6)	(32.2)
Other	4.5	8.7
Net cash flows used in financing activities	(2,245.3)	(679.3)
Net increase (decrease) in cash and cash equivalents	(335.1)	1,019.0
Effect of exchange rate changes on cash and cash equivalents	(12.7)	0.4
Cash and cash equivalents, beginning of the period	2,913.7	1,224.6
Cash and cash equivalents, end of the period	$ 2,591.3	$ 2,243.2